Congxia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Congxia Wang has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Weidong Ma
Xi An Jiao Tong Univ, Dept Cardiovasc Med, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
4 shared publicationsTuo Han
Xi An Jiao Tong Univ, Dept Cardiovasc Med, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
3 shared publicationsYajie Fan
Department of Cardiology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
3 shared publicationsChunyan Zhang
Xi An Jiao Tong Univ, Dept Cardiovasc Med, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
2 shared publicationsShan Jia
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
2 shared publicationsC. Zhang
Department of Cardiovascular Medicine the Second Affiliated Hospital of Medical School Xi'an Jiaotong University Xi'an Shaanxi China
1 shared publication
Latest Publications
- 1 January 2023
- Vol. 15 (3) , 2207-2219
Development and validation of a model to predict the risk of hypertension using anthropometric indicators in the Chinese population: a retrospective cohort study
Background: The prevalence of hypertension and obesity in China has sharply increased in recent decades. We aimed to develop and validate a novel model for predicting the risk of hypertension based on anthropometric indicators relating to obesity in the general population of China. Methods: In this retrospective study, 6196 participants from the China Health and Nutrition Survey (CHNS) during the 2009-2015 waves were included. Risk factors for hypertension were assessed by LASSO regression combined with multivariate logistic regression analysis. A nomogram was developed as a predictive model based on the screening prediction factors. The discrimination and calibration of the model were evaluated by receiver operating curve (ROC) and calibration plots, respectively. Decision curve analysis (DCA) was used to evaluate the clinical application value of the model. Results: A total of 6196 participants were divided into two sets at a ratio of 7:3, using computer-generated random numbers: 4337 individuals were assigned to the training set and 1859 to the validation set. The training set was divided into a hypertension group (n = 1016) and a non-hypertension group (n = 3321) based on the follow-up outcomes for hypertension. Predictive factors of hypertension included age, drinking, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR) and arm-to-height ratio (AHtR) at baseline as predictors. The area under the ROC curve (AUC) for the training and validation sets was 0.906 (95% CI: 0.897-0.915) and 0.905 (95% CI: 0.887-0.922), respectively. In bootstrap validation, the C-index was 0.905 (95% CI: 0.888-0.921). The model also had good predictive accuracy according to the calibration plot. DCA demonstrated that people would benefit more when the threshold probability was between 5% and 80%. Conclusion: A nomogram model was successfully established to effectively predict the risk of hypertension based on anthropometric indicators. The model could be a feasible tool for hypertension screening in the general population of China.
- 1 January 2023
- Vol. 15 (3) , 2207-2219
Development and validation of a model to predict the risk of hypertension using anthropometric indicators in the Chinese population: a retrospective cohort study
Background: The prevalence of hypertension and obesity in China has sharply increased in recent decades. We aimed to develop and validate a novel model for predicting the risk of hypertension based on anthropometric indicators relating to obesity in the general population of China. Methods: In this retrospective study, 6196 participants from the China Health and Nutrition Survey (CHNS) during the 2009-2015 waves were included. Risk factors for hypertension were assessed by LASSO regression combined with multivariate logistic regression analysis. A nomogram was developed as a predictive model based on the screening prediction factors. The discrimination and calibration of the model were evaluated by receiver operating curve (ROC) and calibration plots, respectively. Decision curve analysis (DCA) was used to evaluate the clinical application value of the model. Results: A total of 6196 participants were divided into two sets at a ratio of 7:3, using computer-generated random numbers: 4337 individuals were assigned to the training set and 1859 to the validation set. The training set was divided into a hypertension group (n = 1016) and a non-hypertension group (n = 3321) based on the follow-up outcomes for hypertension. Predictive factors of hypertension included age, drinking, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR) and arm-to-height ratio (AHtR) at baseline as predictors. The area under the ROC curve (AUC) for the training and validation sets was 0.906 (95% CI: 0.897-0.915) and 0.905 (95% CI: 0.887-0.922), respectively. In bootstrap validation, the C-index was 0.905 (95% CI: 0.888-0.921). The model also had good predictive accuracy according to the calibration plot. DCA demonstrated that people would benefit more when the threshold probability was between 5% and 80%. Conclusion: A nomogram model was successfully established to effectively predict the risk of hypertension based on anthropometric indicators. The model could be a feasible tool for hypertension screening in the general population of China.
- Open Access
- 22 April 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (20) , 12858
Correction: A fluorescent biosensor for cardiac biomarker myoglobin detection based on carbon dots and deoxyribonuclease I-aided target recycling signal amplification
Correction for ‘A fluorescent biosensor for cardiac biomarker myoglobin detection based on carbon dots and deoxyribonuclease I-aided target recycling signal amplification’ by Jishun Chen et al. , RSC Adv. , 2019, 9 , 4463–4468, https://doi.org/10.1039/C8RA09459D.
- 22 April 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (20) , 12858
Open AccessCorrection: A fluorescent biosensor for cardiac biomarker myoglobin detection based on carbon dots and deoxyribonuclease I-aided target recycling signal amplification
Correction for ‘A fluorescent biosensor for cardiac biomarker myoglobin detection based on carbon dots and deoxyribonuclease I-aided target recycling signal amplification’ by Jishun Chen et al. , RSC Adv. , 2019, 9 , 4463–4468, https://doi.org/10.1039/C8RA09459D.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Adipocyte
- Vol. 10 (1) , 446-455
Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice
With the increasing obesity prevalence, the rates of obesity-related diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have increased dramatically. Dapagliflozin, one of the sodium glucose cotransporter inhibitors, not only exerts hypoglycaemic effects through increasing urinary glucose excretion but alsoreprograms the metabolic system, leading to benefits in metabolic and cardiovascular diseases. In this study, pre-established obese mice on a high-fat diet were given dapagliflozin by gavage for fourweeks. It showed that dapagliflozin can enhance fat utilization and browning of adipose tissue and improve local oxidative stress, thus inhibiting fat accumulation and hepatic steatosis without disturbance in body weight or plasma glycolipid level. Overall, our study highlights the potential clinical application of SGLT2 inhibition in the prevention of obesity and related metabolic diseases, such as insulin resistance, NAFLD, and diabetes.
- 1 January 2021
- Published by Taylor & Francis in Adipocyte
- Vol. 10 (1) , 446-455
Open AccessSodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice
With the increasing obesity prevalence, the rates of obesity-related diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have increased dramatically. Dapagliflozin, one of the sodium glucose cotransporter inhibitors, not only exerts hypoglycaemic effects through increasing urinary glucose excretion but alsoreprograms the metabolic system, leading to benefits in metabolic and cardiovascular diseases. In this study, pre-established obese mice on a high-fat diet were given dapagliflozin by gavage for fourweeks. It showed that dapagliflozin can enhance fat utilization and browning of adipose tissue and improve local oxidative stress, thus inhibiting fat accumulation and hepatic steatosis without disturbance in body weight or plasma glycolipid level. Overall, our study highlights the potential clinical application of SGLT2 inhibition in the prevention of obesity and related metabolic diseases, such as insulin resistance, NAFLD, and diabetes.
- 1 December 2018
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 72 (6) , 270-276
Magnesium Citrate Protects Against Vascular Calcification in an Adenine-induced Chronic Renal Failure Rat Model
Background: Hypomagnesemia was identified as a strong risk factor for cardiovascular disease in patients with chronic renal failure (CRF). However, the effects of magnesium (Mg) on vascular calcification (VC) have not been fully elucidated. Thus, we aim to determine the effects of Mg citrate (MgCit) on VC in CRF rats. Methods: Rats were divided into 5 groups: group 1 (normal diet), group 2 (normal diet with MgCit), group 3 (the VC model of CRF induced by 0.75% adenine and 0.9% phosphorus diet from day 1 to day 28), group 4 (group 3 treated with low-dose MgCit from day 1 to day 42), and group 5 (same as group 3 except the high-dose MgCit). All rats were killed at day 43 with collection of blood and aortas. Then, serum biochemical parameters, VC-related staining, calcium and P contents, alkaline phosphatase contents and activity, expression of alpha smooth muscle actin, and runt-related transcription factor 2 (RUNX2) in aortas were assessed. Results: Group 3 had extensive VC. The VC degree decreased in groups 4 and 5 in a dose-depended manner with reduced calcium content, P levels, alkaline phosphatase content and activity, and protein levels of RUNX2 and increased protein levels of alpha smooth muscle actin in aortas. Conclusions: MgCit exerted a protective role in VC in adenine-induced CRF rats; thus, it may be a potential drug for the prevention of VC in patients with CRF.
- 1 December 2018
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 72 (6) , 270-276
Magnesium Citrate Protects Against Vascular Calcification in an Adenine-induced Chronic Renal Failure Rat Model
Background: Hypomagnesemia was identified as a strong risk factor for cardiovascular disease in patients with chronic renal failure (CRF). However, the effects of magnesium (Mg) on vascular calcification (VC) have not been fully elucidated. Thus, we aim to determine the effects of Mg citrate (MgCit) on VC in CRF rats. Methods: Rats were divided into 5 groups: group 1 (normal diet), group 2 (normal diet with MgCit), group 3 (the VC model of CRF induced by 0.75% adenine and 0.9% phosphorus diet from day 1 to day 28), group 4 (group 3 treated with low-dose MgCit from day 1 to day 42), and group 5 (same as group 3 except the high-dose MgCit). All rats were killed at day 43 with collection of blood and aortas. Then, serum biochemical parameters, VC-related staining, calcium and P contents, alkaline phosphatase contents and activity, expression of alpha smooth muscle actin, and runt-related transcription factor 2 (RUNX2) in aortas were assessed. Results: Group 3 had extensive VC. The VC degree decreased in groups 4 and 5 in a dose-depended manner with reduced calcium content, P levels, alkaline phosphatase content and activity, and protein levels of RUNX2 and increased protein levels of alpha smooth muscle actin in aortas. Conclusions: MgCit exerted a protective role in VC in adenine-induced CRF rats; thus, it may be a potential drug for the prevention of VC in patients with CRF.
- 1 October 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 505 (1) , 119-125
Circ-SATB2 upregulates STIM1 expression and regulates vascular smooth muscle cell proliferation and differentiation through miR-939
- 1 October 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 505 (1) , 119-125
Circ-SATB2 upregulates STIM1 expression and regulates vascular smooth muscle cell proliferation and differentiation through miR-939
- Open Access
- 30 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (5) , 7350-7356
Variants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population
Variants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population
- 30 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (5) , 7350-7356
Open AccessVariants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population
Variants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population
- 9 October 2013
- Published by Elsevier in Experimental Gerontology
- Vol. 48 (12) , 1449-1454
Normal reference value of whole blood viscosity (230s−1) of old women and geographical factors
- 9 October 2013
- Published by Elsevier in Experimental Gerontology
- Vol. 48 (12) , 1449-1454
Normal reference value of whole blood viscosity (230s−1) of old women and geographical factors
- 19 May 2013
- Published by Springer Nature in International Journal of Biometeorology
- Vol. 58 (5) , 769-779
Predictive models and spatial variations of vital capacity in healthy people from 6 to 84 years old in China based on geographical factors
- 19 May 2013
- Published by Springer Nature in International Journal of Biometeorology
- Vol. 58 (5) , 769-779
Predictive models and spatial variations of vital capacity in healthy people from 6 to 84 years old in China based on geographical factors
- 30 May 2012
- Published by Wiley in Internal Medicine Journal
- Vol. 42 (10) , 1078-1087
Meta‐analysis of amiodarone versus beta‐blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery
Background: Current guidelines recommend beta‐blocker as the first‐line preventive treatment of atrial fibrillation (AF) after cardiac surgery; if beta‐blocker therapy is contraindicated, then amiodarone is recommended. There is still lack of strong evidence of directly comparing the efficacy of amiodarone and beta‐blocker in preventing postoperative AF (POAF).Aim: This meta‐analysis was to determine whether amiodarione and beta‐blocker are equally effective and safe, or one is superior in preventing POAF.Methods: We searched the Medline, Web of Science, Cochrane Library databases and clinical trial databases for related articles published from January 1990 to October 2011. The primary outcome was development of AF after cardiac surgery. We used random‐effects model when there was significant heterogeneity between trials and fixed‐effects method when heterogeneity was negligible. Moreover, subgroup and sensitivity analyses were also performed.Results: We identified totally six trials, which involved 1033 patients. The amiodarone group did not significantly differ from the beta‐blocker group in AF occurrence (risk ratio 0.77, 95% confidence interval 0.55 to 1.06, P = 0.11) or the length of hospital stay (weighted mean difference −0.05 day, 95% confidence interval −0.64 to 0.54, P = 0.86). Subgroup analysis stratified by different beta‐blockers revealed that amiodarone significantly improved POAF as compared with propranolol. In addition, there was no difference in adverse events after operation.Conclusion: These data indicate that the occurrence of AF and length of hospital stay after surgery are similar in the amiodarone and beta‐blocker groups.
- 30 May 2012
- Published by Wiley in Internal Medicine Journal
- Vol. 42 (10) , 1078-1087
Meta‐analysis of amiodarone versus beta‐blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery
Background: Current guidelines recommend beta‐blocker as the first‐line preventive treatment of atrial fibrillation (AF) after cardiac surgery; if beta‐blocker therapy is contraindicated, then amiodarone is recommended. There is still lack of strong evidence of directly comparing the efficacy of amiodarone and beta‐blocker in preventing postoperative AF (POAF).Aim: This meta‐analysis was to determine whether amiodarione and beta‐blocker are equally effective and safe, or one is superior in preventing POAF.Methods: We searched the Medline, Web of Science, Cochrane Library databases and clinical trial databases for related articles published from January 1990 to October 2011. The primary outcome was development of AF after cardiac surgery. We used random‐effects model when there was significant heterogeneity between trials and fixed‐effects method when heterogeneity was negligible. Moreover, subgroup and sensitivity analyses were also performed.Results: We identified totally six trials, which involved 1033 patients. The amiodarone group did not significantly differ from the beta‐blocker group in AF occurrence (risk ratio 0.77, 95% confidence interval 0.55 to 1.06, P = 0.11) or the length of hospital stay (weighted mean difference −0.05 day, 95% confidence interval −0.64 to 0.54, P = 0.86). Subgroup analysis stratified by different beta‐blockers revealed that amiodarone significantly improved POAF as compared with propranolol. In addition, there was no difference in adverse events after operation.Conclusion: These data indicate that the occurrence of AF and length of hospital stay after surgery are similar in the amiodarone and beta‐blocker groups.